Biomarkers to Predict Cancer Therapy-related Cardiotoxicity

Description

This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.

Conditions

Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm

Talk to us

Study Overview

On this page

Study Details

Study overview

This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.

Biomarkers to Predict Cancer Therapy-Related Cardiotoxicity

Biomarkers to Predict Cancer Therapy-related Cardiotoxicity

Condition
Hematopoietic and Lymphatic System Neoplasm
Intervention / Treatment

-

Contacts and Locations

Scottsdale

Mayo Clinic in Arizona, Scottsdale, Arizona, United States, 85259

Jacksonville

Mayo Clinic in Florida, Jacksonville, Florida, United States, 32224-9980

Tampa

Moffitt Cancer Center, Tampa, Florida, United States, 33612

Rochester

Mayo Clinic in Rochester, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 18 years of age or older
  • * Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy
  • * One of the following:
  • * Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment
  • * Completed chemotherapy with no cardiotoxicity at least two years post treatment
  • * Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity
  • * An understanding of the protocol and its requirements, risks, and discomforts
  • * The ability and willingness to sign an informed consent

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Nadine Norton, PhD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2026-06-01